PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 30898012-6 2020 We found that pharmacological activation of PPARA by the PPARA agonists gemfibrozil and Wy14643 induces autophagy in human microglia (HM) cells and U251 human glioma cells stably expressing the human APP (amyloid beta precursor protein) mutant (APP-p.M671L) and this effect is PPARA-dependent. Gemfibrozil 72-83 peroxisome proliferator activated receptor alpha Homo sapiens 44-49 33514677-9 2021 These findings highlight the importance of PPARalpha-dependent astroglial GDNF pathway in gemfibrozil-mediated protection of dopaminergic neurons in an animal model of PD and suggest possible therapeutic use of gemfibrozil in PD patients.SIGNIFICANCE STATEMENT:Increasing the level of glial cell-derived neurotrophic factor (GDNF) in the brain is important for the protection of dopamine neurons in Parkinson"s disease (PD). Gemfibrozil 90-101 peroxisome proliferator activated receptor alpha Homo sapiens 43-52 33514677-9 2021 These findings highlight the importance of PPARalpha-dependent astroglial GDNF pathway in gemfibrozil-mediated protection of dopaminergic neurons in an animal model of PD and suggest possible therapeutic use of gemfibrozil in PD patients.SIGNIFICANCE STATEMENT:Increasing the level of glial cell-derived neurotrophic factor (GDNF) in the brain is important for the protection of dopamine neurons in Parkinson"s disease (PD). Gemfibrozil 211-222 peroxisome proliferator activated receptor alpha Homo sapiens 43-52 33514677-11 2021 Here, we delineate that gemfibrozil, a lipid-lowering drug, stimulates GDNF in astrocytes via peroxisome proliferator-activated receptor alpha (PPARalpha). Gemfibrozil 24-35 peroxisome proliferator activated receptor alpha Homo sapiens 144-153 33514677-12 2021 Moreover, gemfibrozil protected nigral neurons, normalized striatal fibers and neurotransmitters, and improved locomotor activities from MPTP toxicity via PPARalpha-dependent astroglial GDNF pathway. Gemfibrozil 10-21 peroxisome proliferator activated receptor alpha Homo sapiens 155-164 30898012-6 2020 We found that pharmacological activation of PPARA by the PPARA agonists gemfibrozil and Wy14643 induces autophagy in human microglia (HM) cells and U251 human glioma cells stably expressing the human APP (amyloid beta precursor protein) mutant (APP-p.M671L) and this effect is PPARA-dependent. Gemfibrozil 72-83 peroxisome proliferator activated receptor alpha Homo sapiens 57-62 30898012-6 2020 We found that pharmacological activation of PPARA by the PPARA agonists gemfibrozil and Wy14643 induces autophagy in human microglia (HM) cells and U251 human glioma cells stably expressing the human APP (amyloid beta precursor protein) mutant (APP-p.M671L) and this effect is PPARA-dependent. Gemfibrozil 72-83 peroxisome proliferator activated receptor alpha Homo sapiens 57-62 30898012-9 2020 These results indicated that PPARA is an important factor regulating autophagy in the clearance of Abeta and suggested gemfibrozil be assessed as a possible treatment for AD. Gemfibrozil 119-130 peroxisome proliferator activated receptor alpha Homo sapiens 29-34 30260990-0 2018 Testing the PPAR hypothesis of tobacco use disorder in humans: A randomized trial of the impact of gemfibrozil (a partial PPARalpha agonist) in smokers. Gemfibrozil 99-110 peroxisome proliferator activated receptor alpha Homo sapiens 122-131 30680004-0 2019 Gemfibrozil reduces lipid accumulation in SMMC-7721 cells via the involvement of PPARalpha and SREBP1. Gemfibrozil 0-11 peroxisome proliferator activated receptor alpha Homo sapiens 81-90 30680004-6 2019 Upregulation of peroxisome proliferator-activated receptor alpha (PPARalpha) protein and sterol regulatory element-binding protein 1 (SREBP1) was detected following treatment with GEM. Gemfibrozil 180-183 peroxisome proliferator activated receptor alpha Homo sapiens 16-64 30680004-6 2019 Upregulation of peroxisome proliferator-activated receptor alpha (PPARalpha) protein and sterol regulatory element-binding protein 1 (SREBP1) was detected following treatment with GEM. Gemfibrozil 180-183 peroxisome proliferator activated receptor alpha Homo sapiens 66-75 30260990-2 2018 Our goal was to investigate the potential of gemfibrozil, a PPARalpha agonist, on reducing tobacco smoking in humans. Gemfibrozil 45-56 peroxisome proliferator activated receptor alpha Homo sapiens 60-69 29662003-9 2018 The PPAR system thus offers an important hope in the management of atherogenic dyslipidemias, although concerns regarding potential adverse events such as the rise of plasma creatinine, gallstone formation, drug-drug interactions (i.e., gemfibrozil) and myopathy should also be acknowledged. Gemfibrozil 237-248 peroxisome proliferator activated receptor alpha Homo sapiens 4-8 29534628-3 2018 Besides being a lipid-regulating agent, gemfibrozil is an agonist of peroxisome proliferator-activated receptor-alpha (PPAR-alpha). Gemfibrozil 40-51 peroxisome proliferator activated receptor alpha Homo sapiens 119-129 24180432-4 2014 Chemical-specific and mechanistic data support concordance of temporal and dose-response relationships for the key events associated with many PPARalpha activators including a phthalate ester plasticizer di(2-ethylhexyl) phthalate (DEHP) and the drug gemfibrozil. Gemfibrozil 251-262 peroxisome proliferator activated receptor alpha Homo sapiens 143-152 28752027-3 2017 PPARs constitute a recognized druggable target and indeed several classes of drugs used in the treatment of metabolic disease symptoms, such as dyslipidemia (fibrates, e.g. fenofibrate and gemfibrozil) and diabetes (thiazolidinediones, e.g. rosiglitazone and pioglitazone) are ligands for the various PPAR isoforms. Gemfibrozil 189-200 peroxisome proliferator activated receptor alpha Homo sapiens 0-4 25750174-5 2015 This study demonstrates that gemfibrozil, an agonist of peroxisome proliferator-activated receptor (PPAR) alpha, alone and in conjunction with all-trans-retinoic acid is capable of enhancing TFEB in brain cells. Gemfibrozil 29-40 peroxisome proliferator activated receptor alpha Homo sapiens 56-111 25750174-6 2015 We also observed that PPARalpha, but not PPARbeta and PPARgamma, is involved in gemfibrozil-mediated up-regulation of TFEB. Gemfibrozil 80-91 peroxisome proliferator activated receptor alpha Homo sapiens 22-31 28343425-5 2017 Expert opinion: In addition to the aim of improving lipid profile with fibrates, the interest in new PPAR-alpha activators stems from the need to overcome some of the clinical problems encountered with dose-dependent adverse events; a rise of plasma creatinine, gallstone formation, drug-drug interactions (i.e. gemfibrozil), and myopathy. Gemfibrozil 312-323 peroxisome proliferator activated receptor alpha Homo sapiens 101-111 25147562-2 2014 The present study aimed at evaluating how 3 PPARalpha agonists, namely, fenofibrate, gemfibrozil, and Wy14,643, affect bilirubin synthesis and metabolism. Gemfibrozil 85-96 peroxisome proliferator activated receptor alpha Homo sapiens 44-53 21889235-0 2011 Discovery of gemfibrozil analogues that activate PPARalpha and enhance the expression of gene CPT1A involved in fatty acids catabolism. Gemfibrozil 13-24 peroxisome proliferator activated receptor alpha Homo sapiens 49-58 22879602-4 2012 Although gemfibrozil is a known activator of peroxisome proliferator-activated receptor-alpha (PPAR-alpha), we were unable to detect PPAR-alpha in either gemfibrozil-treated or untreated human oligodendrocytes, and gemfibrozil increased the expression of myelin genes in oligodendrocytes isolated from both wild type and PPAR-alpha(-/-) mice. Gemfibrozil 9-20 peroxisome proliferator activated receptor alpha Homo sapiens 45-93 22879602-4 2012 Although gemfibrozil is a known activator of peroxisome proliferator-activated receptor-alpha (PPAR-alpha), we were unable to detect PPAR-alpha in either gemfibrozil-treated or untreated human oligodendrocytes, and gemfibrozil increased the expression of myelin genes in oligodendrocytes isolated from both wild type and PPAR-alpha(-/-) mice. Gemfibrozil 9-20 peroxisome proliferator activated receptor alpha Homo sapiens 95-105 21889235-1 2011 A new series of gemfibrozil analogues conjugated with alpha-asarone, trans-stilbene, chalcone, and their bioisosteric modifications were synthesized and evaluated to develop PPARalpha agonists. Gemfibrozil 16-27 peroxisome proliferator activated receptor alpha Homo sapiens 174-183 21966330-2 2011 Fibrates, including fenofibrate, gemfibrozil, benzafibrate, ciprofibrate, and clofibrate act on PPAR alpha to reduce the level of hypertriglyceridemia. Gemfibrozil 33-44 peroxisome proliferator activated receptor alpha Homo sapiens 96-106 19779008-5 2010 This is of great interest since we have recently shown that gemfibrozil, a drug used to treat hyperlipidemia in humans and a synthetic ligand of PPAR alpha, significantly reduces the mortality associated with influenza infections in mice. Gemfibrozil 60-71 peroxisome proliferator activated receptor alpha Homo sapiens 145-155 20953357-7 2010 These events are causally related to hepatotoxicity and hepatocarcinogenicity of gemfibrozil in rodents via peroxisome proliferator activated receptor-alpha (PPARalpha) activation; however, there is widespread evidence that activation of PPARalpha in humans results in expression of genes involved in lipid metabolism, but not in hepatocellular proliferation. Gemfibrozil 81-92 peroxisome proliferator activated receptor alpha Homo sapiens 108-156 20953357-7 2010 These events are causally related to hepatotoxicity and hepatocarcinogenicity of gemfibrozil in rodents via peroxisome proliferator activated receptor-alpha (PPARalpha) activation; however, there is widespread evidence that activation of PPARalpha in humans results in expression of genes involved in lipid metabolism, but not in hepatocellular proliferation. Gemfibrozil 81-92 peroxisome proliferator activated receptor alpha Homo sapiens 158-167 20953357-7 2010 These events are causally related to hepatotoxicity and hepatocarcinogenicity of gemfibrozil in rodents via peroxisome proliferator activated receptor-alpha (PPARalpha) activation; however, there is widespread evidence that activation of PPARalpha in humans results in expression of genes involved in lipid metabolism, but not in hepatocellular proliferation. Gemfibrozil 81-92 peroxisome proliferator activated receptor alpha Homo sapiens 238-247 18799592-1 2008 The first generation peroxisome proliferator-activated receptor (PPAR) alpha agonist gemfibrozil reduces the risk of major cardiovascular events; therefore, more potent PPARalpha agonists for the treatment of cardiovascular diseases have been actively sought. Gemfibrozil 85-96 peroxisome proliferator activated receptor alpha Homo sapiens 65-69 19376321-4 2009 The objective of this study was to investigate whether the PPARalpha activator gemfibrozil prevents or delays the development of AF in patients with coronary heart disease. Gemfibrozil 79-90 peroxisome proliferator activated receptor alpha Homo sapiens 59-68 18420459-6 2008 An experimental study has shown that the fibrate gemfibrozil, a peroxisome proliferator-activated receptor (PPAR) alpha agonist, reduces mortality in H2N2 influenza virus-infected mice. Gemfibrozil 49-60 peroxisome proliferator activated receptor alpha Homo sapiens 108-112 15618549-0 2005 Regulation of human apoA-I by gemfibrozil and fenofibrate through selective peroxisome proliferator-activated receptor alpha modulation. Gemfibrozil 30-41 peroxisome proliferator activated receptor alpha Homo sapiens 76-124 18092840-13 2008 In clinical trials of gemfibrozil, a PPARalpha ligand, significantly fewer patients treated with this lipid-lowering drug were diagnosed with melanoma as compared to those in the control group. Gemfibrozil 22-33 peroxisome proliferator activated receptor alpha Homo sapiens 37-46 17897018-4 2007 Fenofibrate and gemfibrozil are two drugs that act as PPARalpha agonists and are currently in use in the clinical setting. Gemfibrozil 16-27 peroxisome proliferator activated receptor alpha Homo sapiens 54-63 17897018-8 2007 These studies have shown both PPARalpha agonists, gemfibrozil and fenofibrate, confer anti-atherosclerotic effects, partly independent of their metabolic effects. Gemfibrozil 50-61 peroxisome proliferator activated receptor alpha Homo sapiens 30-39 16828346-2 2006 Treatment with a fibrate such as gemfibrozil (a PPAR alpha agonist) has been shown to be especially effective in people with low HDL-C and other features of the metabolic syndrome. Gemfibrozil 33-44 peroxisome proliferator activated receptor alpha Homo sapiens 48-58 16782410-4 2006 PPARalpha is activated by polyunsaturated fatty acids and by fibrate drugs (fenofibrate and gemfibrozil) and controls expression of genes involved in lipid metabolism. Gemfibrozil 92-103 peroxisome proliferator activated receptor alpha Homo sapiens 0-9 16101410-2 2005 The physiological effects of several marketed drugs for the treatment of dyslipidemia (fenofibrate and gemfibrozil) and diabetes (rosiglitazone and pioglitazone) have now been shown to be mediated through PPARalpha and PPARgamma respectively. Gemfibrozil 103-114 peroxisome proliferator activated receptor alpha Homo sapiens 205-214 18678301-1 2008 The weak peroxisome proliferator activated receptor-alpha (PPAR-alpha) agonists gemfibrozil and fenofibrate achieve only small increases in high-density lipoprotein (HDL) cholesterol. Gemfibrozil 80-91 peroxisome proliferator activated receptor alpha Homo sapiens 9-57 18678301-1 2008 The weak peroxisome proliferator activated receptor-alpha (PPAR-alpha) agonists gemfibrozil and fenofibrate achieve only small increases in high-density lipoprotein (HDL) cholesterol. Gemfibrozil 80-91 peroxisome proliferator activated receptor alpha Homo sapiens 59-69 16221474-1 2006 BACKGROUND: The Veterans Affairs HDL Intervention Trial (VA-HIT) showed that gemfibrozil, which activates peroxisome proliferator-activator receptor alpha (PPARalpha), significantly reduced the risk of cardiovascular (CV) events in men with low HDL cholesterol (< 40 mg/dl) and established coronary heart disease. Gemfibrozil 77-88 peroxisome proliferator activated receptor alpha Homo sapiens 156-165 16226225-1 2005 Fibrates such as bezafibrate, gemfibrozil, clofibric acid, ciprofibrate and fenofibrate, are ligands for peroxisome proliferator-activated receptor alpha (PPARalpha), and are used as therapeutic agents in the treatment of hyperlipidemia. Gemfibrozil 30-41 peroxisome proliferator activated receptor alpha Homo sapiens 105-153 16226225-1 2005 Fibrates such as bezafibrate, gemfibrozil, clofibric acid, ciprofibrate and fenofibrate, are ligands for peroxisome proliferator-activated receptor alpha (PPARalpha), and are used as therapeutic agents in the treatment of hyperlipidemia. Gemfibrozil 30-41 peroxisome proliferator activated receptor alpha Homo sapiens 155-164 12746275-5 2003 PPARalpha potentiates fatty acid catabolism in the liver and is the molecular target of the lipid-lowering fibrates (e.g. fenofibrate and gemfibrozil), whereas PPARgamma is essential for adipocyte differentiation and mediates the activity of the insulin-sensitizing thiazolidinediones (e.g. rosiglitazone and pioglitazone). Gemfibrozil 138-149 peroxisome proliferator activated receptor alpha Homo sapiens 0-9 15142970-4 2004 PPARalpha is activated by polyunsaturated fatty acids and oxidized derivatives and by lipid-modifying drugs of the fibrate family, including fenofibrate or gemfibrozil. Gemfibrozil 156-167 peroxisome proliferator activated receptor alpha Homo sapiens 0-9 15100326-7 2004 These results suggest that PPAR alpha agonists such as gemfibrozil and fenofibrate, may be attractive candidates for use in human inflammatory conditions such as multiple sclerosis. Gemfibrozil 55-66 peroxisome proliferator activated receptor alpha Homo sapiens 27-37 15194003-0 2004 PPARalpha agonists clofibrate and gemfibrozil inhibit cell growth, down-regulate hCG and up-regulate progesterone secretions in immortalized human trophoblast cells. Gemfibrozil 34-45 peroxisome proliferator activated receptor alpha Homo sapiens 0-9 15100326-3 2004 The PPAR alpha agonists, gemfibrozil, ciprofibrate, and fenofibrate, have an excellent track history as oral agents used to treat hypertriglyceridemia. Gemfibrozil 25-36 peroxisome proliferator activated receptor alpha Homo sapiens 4-14 11712864-6 2001 PPAR-alpha activators (gemfibrozil) decrease the risk of coronary heart disease in patients with normal LDL-cholesterol and low HDL-cholesterol (VA-HIT) and they slow the progression of premature coronary atherosclerosis (BECAIT) (bezafibrate), particularly in patients with type 2 diabetes (DAIS) (fenofibrate). Gemfibrozil 23-34 peroxisome proliferator activated receptor alpha Homo sapiens 0-10 12244038-5 2002 Gemfibrozil induced peroxisome proliferator-responsive element (PPRE)-dependent luciferase activity, which was inhibited by the expression of DeltahPPAR-alpha, the dominant-negative mutant of human PPAR-alpha. Gemfibrozil 0-11 peroxisome proliferator activated receptor alpha Homo sapiens 148-158 12172398-0 2002 Influences of the PPAR alpha-L162V polymorphism on plasma HDL(2)-cholesterol response of abdominally obese men treated with gemfibrozil. Gemfibrozil 124-135 peroxisome proliferator activated receptor alpha Homo sapiens 18-28 12172398-1 2002 PURPOSE: The effect of gemfibrozil is mediated by the activation of peroxisome proliferator-activated receptor alpha (PPAR alpha). Gemfibrozil 23-34 peroxisome proliferator activated receptor alpha Homo sapiens 68-116 12172398-1 2002 PURPOSE: The effect of gemfibrozil is mediated by the activation of peroxisome proliferator-activated receptor alpha (PPAR alpha). Gemfibrozil 23-34 peroxisome proliferator activated receptor alpha Homo sapiens 118-128 12172398-2 2002 The objective of this study was to determine whether the lipid response to gemfibrozil therapy is influenced by the PPAR alpha-L162V polymorphism. Gemfibrozil 75-86 peroxisome proliferator activated receptor alpha Homo sapiens 116-126 12172398-5 2002 CONCLUSION: These results suggest that the HDL(2)-C response to gemfibrozil is modulated by the PPAR alpha-L162V polymorphism. Gemfibrozil 64-75 peroxisome proliferator activated receptor alpha Homo sapiens 96-106 11914252-2 2002 METHODS AND RESULTS: We investigated the association between the leucine 162 to valine (L162V) polymorphism and a G to C transversion in intron 7 of the PPARalpha gene and progression of atherosclerosis in the Lopid Coronary Angiography Trial (LOCAT), a trial examining the effect of gemfibrozil treatment on progression of atherosclerosis after bypass surgery and on risk of IHD in the second Northwick Park Heart Study (NPHS2), a prospective study of healthy middle-aged men in the United Kingdom. Gemfibrozil 284-295 peroxisome proliferator activated receptor alpha Homo sapiens 153-162 12244038-4 2002 Since gemfibrozil is known to activate peroxisome proliferator-activated receptor-alpha (PPAR-alpha), we investigated the role of PPAR-alpha in gemfibrozil-mediated inhibition of iNOS. Gemfibrozil 6-17 peroxisome proliferator activated receptor alpha Homo sapiens 39-87 12244038-4 2002 Since gemfibrozil is known to activate peroxisome proliferator-activated receptor-alpha (PPAR-alpha), we investigated the role of PPAR-alpha in gemfibrozil-mediated inhibition of iNOS. Gemfibrozil 6-17 peroxisome proliferator activated receptor alpha Homo sapiens 89-99 11474570-5 2001 PPAR-alpha activators (fibrates) improve plasma lipid levels and decrease CHD risk in patients with low HDL-cholesterol (gemfibrozil). Gemfibrozil 121-132 peroxisome proliferator activated receptor alpha Homo sapiens 0-10 10494028-7 1999 Under serum conditions allowing apo CIII secretion, treatment with the peroxisome-proliferator activated receptor (PPAR)alpha activators fenofibrate, gemfibrozil and Wy-14643 result in a marked lowering of apo CIII secretion and gene expression, this effect being most pronounced with Wy-14643. Gemfibrozil 150-161 peroxisome proliferator activated receptor alpha Homo sapiens 115-125 9484993-3 1998 Fibrates like gemfibrozil are well-known PPARalpha activators and are used in the treatment of hyperlipidemia. Gemfibrozil 14-25 peroxisome proliferator activated receptor alpha Homo sapiens 41-50 9484993-4 1998 We show that the RXR ligand LGD1069 (Targretin), like gemfibrozil, can activate the PPARalpha/RXR signal-transduction pathway, including transactivation of the bifunctional enzyme or acyl-CoA oxidase response elements in a cotransfection assay. Gemfibrozil 54-65 peroxisome proliferator activated receptor alpha Homo sapiens 84-93